Although our findings are based on small-scale studies with high heterogeneity, the preliminary results suggest merit in the use of PSMA PET/CT in RCC, particularly when performed for restaging of metastatic or recurrent disease. This evidence concerns the gene FOLH1 and renal cell carcinoma.